AB-729 / Arbutus 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    News 
5 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AB-729 / Arbutus
NCT04820686: A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection

Recruiting
2a
60
Europe, Canada, RoW
VBR, Vebicorvir, ABI-H0731, AB-729, SOC NrtI, Entecavir (ETV), Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide (TAF)
Assembly Biosciences, Arbutus Biopharma Corporation
Chronic Hepatitis B
07/23
07/23
NCT04980482: Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

Recruiting
2
40
US, RoW
AB-729, Peg-IFN╬▒-2a, pegylated interferon alpha 2a
Arbutus Biopharma Corporation
Chronic Hepatitis b
03/23
08/24
ACTRN12620000295943: A Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-729 Administered by Subcutaneous Injection to Subjects with Chronic Hepatitis B Infection

Recruiting
1
35
 
Arbutus Biopharma Corporation, Arbutus Biopharma Corporation
Chronic Hepatitis B Infection (CHB)
 
 
ACTRN12619000954123: A Study to Investigate the Safety, Tolerability and Pharmacokinetics, of AB-729 Administered by Subcutaneous Injection to Healthy Subjects (part 1)

Active, not recruiting
1
24
 
Arbutus Biopharma Corporation, Arbutus Biopharma Corporation
Chronic Hepatitis B Infection
 
 
ACTRN12619001197123: A Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-729 Administered by Subcutaneous Injection to Subjects with Chronic Hepatitis B Infection

Active, not recruiting
1
167
 
Arbutus Biopharma Corporation, Arbutus Biopharma Corporation
Chronic Hepatitis B Infection (CHB)
 
 

Download Options